DEA Publishes Proposal to Reschedule Hydrocodone ProductsDEA Publishes Proposal to Reschedule Hydrocodone Products

Following advice from FDA and HHS, DEA published a formal proposal to reclassify hydrocodone combo products as Schedule II controlled substances. Meanwhile, public pushback of Zohydro approval grows. Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news